Skip to main content
Top
Published in: Brain Tumor Pathology 2/2015

01-04-2015 | Original Article

Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas

Authors: Yukihiko Sonoda, Ichiyoo Shibahara, Tomohiro Kawaguchi, Ryuta Saito, Masayuki Kanamori, Mika Watanabe, Hiroyoshi Suzuki, Toshihiro Kumabe, Teiji Tominaga

Published in: Brain Tumor Pathology | Issue 2/2015

Login to get access

Abstract

The aim of this study was to determine if molecular alterations are associated with tumor location and radiological characteristics in anaplastic gliomas. We performed a retrospective analysis of 122 anaplastic gliomas for molecular alterations (IDH1/2 mutations, TP53 mutations, and 1p19q co-deletion) to compare MRI features (location and image characteristics). We observed that IDH mutation is strongly associated with frontal location (P = 0.001). However, 13 tumors not located in the cerebral cortex were IDH intact tumors (P < 0.0001). While IDH mutation and TP53 mutation are significantly associated with AA (p < 0.0001), IDH mutation and 1p19q co-deletion were significantly associated with AO/AOA (p < 0.0001). No tumors with IDH mutation and 1p19q co-deletion infiltrated the temporal lobe (P = 0.003). The tumors with 1p19q co-deletion and histologically diagnosed as AO/AOA were associated with contrast enhancement on MR images (p = 0.007, p = 0.002, respectively) and those with TP53 mutation had a weak association with sharp tumor borders (p = 0.043). MRI features might be useful to predict molecular profiles in anaplastic gliomas.
Literature
1.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon
2.
go back to reference The committee of Brain Tumor Registry of Japan (2014) Report of brain tumor registry of Japan (2001–2004) 13th edn The committee of Brain Tumor Registry of Japan (2014) Report of brain tumor registry of Japan (2001–2004) 13th edn
3.
go back to reference Levin VA, Hess KR, Choucair A et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981–990PubMed Levin VA, Hess KR, Choucair A et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981–990PubMed
4.
go back to reference van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722CrossRefPubMed van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722CrossRefPubMed
5.
go back to reference Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343CrossRefPubMedCentralPubMed Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343CrossRefPubMedCentralPubMed
6.
go back to reference Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561CrossRefPubMed Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561CrossRefPubMed
8.
go back to reference Jenkinson MD, du Plessis DG, Smith TS et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed Jenkinson MD, du Plessis DG, Smith TS et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed
9.
go back to reference Kim JW, Park CK, Park SH et al (2010) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82:224–227CrossRefPubMed Kim JW, Park CK, Park SH et al (2010) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82:224–227CrossRefPubMed
10.
go back to reference Reyes-Botero G, Dehais C, Idbaih A et al (2014) Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16:662–670CrossRefPubMed Reyes-Botero G, Dehais C, Idbaih A et al (2014) Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16:662–670CrossRefPubMed
11.
go back to reference Qi S, Yu L, Li H et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7:1895–1902PubMedCentralPubMed Qi S, Yu L, Li H et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7:1895–1902PubMedCentralPubMed
12.
go back to reference Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998CrossRefPubMed Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998CrossRefPubMed
13.
go back to reference Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355CrossRefPubMed Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355CrossRefPubMed
14.
16.
go back to reference Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490CrossRefPubMedCentralPubMed Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490CrossRefPubMedCentralPubMed
17.
go back to reference Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153CrossRefPubMedCentralPubMed Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153CrossRefPubMedCentralPubMed
Metadata
Title
Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas
Authors
Yukihiko Sonoda
Ichiyoo Shibahara
Tomohiro Kawaguchi
Ryuta Saito
Masayuki Kanamori
Mika Watanabe
Hiroyoshi Suzuki
Toshihiro Kumabe
Teiji Tominaga
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Brain Tumor Pathology / Issue 2/2015
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-014-0211-3

Other articles of this Issue 2/2015

Brain Tumor Pathology 2/2015 Go to the issue